Articles

An eye for the eyes

Biogen, AGTC announce a collaboration for gene-based therapies for select orphan eye diseases
Written byKelsey Kaustinen
| 2 min read

CAMBRIDGE, Mass. & GAINESVILLE, Fla.—A new broad collaboration and license agreement was launched today as Biogen and AGTC paired up to develop gene-based therapies for a number of ophthalmic diseases. The deal's focus is on the development of a portfolio of AGTC's therapeutic programs, including a clinical-stage candidate and a preclinical candidate for orphan diseases of the retina that can cause blindness in children and adults.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of a multicolored protein structure composed of folded ribbon-like strands against a blue and teal background with scattered spherical particles
Learn how advanced analytical methods support the characterization of antibody–C1q interactions and the qualification of analytical binding assays.